New book by Larry Connors Click here Improve your trading - See how
Net income grew 12 percent to $530 million from $472 million reported in the third quarter of 2008. Earnings per diluted share of $0.87 advanced 18 percent from $0.74 per diluted share reported in the prior-year period. The third quarter results include after-tax special charges totaling $69 million (or $0.11 per diluted share) primarily for fixed asset write-offs related to the discontinuation of the company's SOLOMIX drug delivery system in development, and planned retirement costs associated with the SYNDEO PCA Syringe Pump. The company recorded after-tax special charges in the third quarter of 2008 totaling $91 million (or $0.14 per diluted share).
On an adjusted basis, excluding special charges in both years, Baxter's net income of $599 million increased 6 percent in the third quarter from $563 million reported in the third quarter last year. Adjusted earnings per diluted share of $0.98 increased 11 percent from $0.88 per diluted share reported in the prior-year period, and compares favorably with the guidance the company previously provided of $0.95 to $0.97 per diluted share. This financial performance was the result of continued margin expansion, expense leverage and benefits derived from the company's ongoing share repurchase program.
Baxter's global sales of $3.1 billion were flat compared to the third quarter last year. Excluding the impact of foreign currency, Baxter's worldwide sales increased 6 percent. Sales within the United States increased 5 percent to $1.3 billion in the third quarter, while international sales declined 4 percent to $1.8 billion. Excluding the impact of foreign currency, Baxter's international sales grew 7 percent.
Medication Delivery sales of $1.2 billion increased 1 percent (and excluding foreign currency increased 7 percent). Renal sales of $576 million declined 3 percent (and excluding foreign currency increased 4 percent). Contributing to these results was growth across multiple product categories, including products used in peritoneal dialysis (PD) treatment, intravenous therapies, injectable drugs and anesthesia products.
BioScience revenues totaled $1.4 billion in the third quarter, which represents a 2 percent increase over the prior-year period. Excluding foreign currency, BioScience sales advanced 8 percent, reflecting gains across several core franchises. Key drivers of sales performance include continued growth of recombinant therapies, including ADVATE [Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method] for the treatment of hemophilia, antibody therapies and several specialty plasma therapeutics, as well as biosurgery products.
"We continue to leverage the benefits derived from our diversified healthcare model to achieve solid financial performance, despite a challenging global macro-economic environment," said Robert L. Parkinson, Jr., chairman and chief executive officer. "Given our strong financial position, geographic presence, and the medically-necessary nature of Baxter's products, Baxter is well-positioned to capitalize on opportunities across a broad array of therapeutic areas."
Nine-Month Results
For the first nine months of 2009, Baxter's net income totaled $1.6 billion, an increase of 13 percent. Earnings per diluted share of $2.66 advanced 18 percent over $2.26 per diluted share reported in the prior-year period. On an adjusted basis, excluding special items from both years, Baxter's net income of $1.7 billion increased 8 percent over $1.6 billion reported for the same period last year. Adjusted earnings per diluted share for the nine-month period increased 12 percent to $2.77 per diluted share, from $2.47 per diluted share reported in 2008.
Baxter's global sales in the first nine months of the year totaled $9.1 billion, and declined 1 percent from $9.2 billion reported in the prior-year period. Excluding the impact of foreign currency, sales growth for the first nine months of 2009 was 7 percent. Sales within the United States totaled $3.9 billion, an increase of 6 percent over the same period last year, while international sales declined 6 percent to $5.2 billion. Excluding the impact of foreign currency, Baxter's international sales grew 8 percent.
Recent Highlights
Baxter has achieved a number of scientific and commercial milestones over the last several months, including:
-- The commercial launch of HYLENEX recombinant (hyaluronidase human injection) in the United States for use in pediatric rehydration. HYLENEX, an enzyme, allows fluids to be administered under the skin (subcutaneously) rather than through a vein. This allows for rapid treatment initiation and delivery of intravenous (IV)-like fluid rates, which can help lead to successful rehydration of children in a less invasive manner.
-- Marketing authorization from the European Commission for CELVAPAN H1N1 pandemic vaccine using Baxter's Vero cell technology. CELVAPAN H1N1 is the first cell culture-based and non-adjuvanted pandemic influenza vaccine to receive marketing authorization in the European Union.
-- Completion of the seasonal influenza Phase III confirmatory study in healthy adults in the United States. The company expects final study results to be available by the end of this year, to support filing for regulatory approval in the United States in the first half of 2010.
-- Initiation of a Phase III study evaluating the use of ARTISS [Fibrin Sealant (Human)] in facial surgery in the United States. Currently, ARTISS is the first and only slow-setting fibrin sealant indicated for use in adhering skin grafts in adult and pediatric burn patients. ARTISS was developed using Baxter's proven fibrin sealant technology platform and is the newest agent in the company's expanding biosurgery portfolio.
-- Filing an Investigational Device Exemption (IDE) with the U.S. Food and Drug Administration (FDA) to begin a clinical study to collect safety and effectiveness data required for a 510(k) application for a new home hemodialysis system.
-- Completion of the acquisition of certain assets related to Edwards Lifesciences Corporation's hemofiltration product line, also known as Continuous Renal Replacement Therapy (CRRT). CRRT provides a method of continuous yet adjustable fluid removal that can gradually remove excess fluid and waste products that build up with the acute impairment of kidney function, and is usually administered in an intensive care setting in the hospital.
Fourth Quarter and Full-Year 2009 Outlook
Baxter also announced today its guidance for fourth quarter 2009 and updated its guidance for the full year.
For the fourth quarter of 2009, Baxter expects sales growth, excluding the impact of foreign currency, of 6 to 8 percent. Based on the company's outlook for foreign exchange rates, the company expects reported sales including the impact of foreign currency to increase 8 to 10 percent over the prior-year period. Baxter also expects to achieve earnings per diluted share of $1.02 to $1.04, before any special items, in the fourth quarter.
For the full year, Baxter expects sales growth, excluding the impact of foreign currency, to increase 7 to 8 percent. Based on the company's outlook for foreign exchange rates, Baxter expects reported sales growth to increase approximately 0 to 1 percent. In addition, the company expects earnings per diluted share of $3.79 to $3.81, before any special items, and continues to expect cash flow from operations to total more than $2.6 billion.
A webcast of Baxter's third quarter conference call for investors can be accessed live from a link on the company's website at www.baxter.com beginning at 7:30 a.m. CDT on October 15, 2009. Please visit Baxter's website for more information regarding this and future investor events and webcasts.
Baxter International Inc., through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide.
This release includes forward-looking statements concerning the company's financial results and outlook for 2009. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: demand for and market acceptance risks for new and existing products, such as ADVATE, and other technologies; future actions of regulatory bodies and other governmental authorities, including the FDA and foreign counterparts, that could delay, limit or suspend product development, manufacturing or sales or result in sanctions; product quality or patient safety concerns leading to product recalls, withdrawals, launch delays, litigation, or declining sales; additional legislation or regulation which may affect pricing, reimbursement and rebate policies of government agencies and private payers or other elements of the company's business; production yields, regulatory clearances and customers' final purchase commitments with respect to the company's pandemic vaccine; product development risks; inventory reductions or fluctuations in buying patterns by wholesalers or distributors; the impact of geographic and product mix on the company's sales; the impact of competitive products and pricing, including generic competition, drug reimportation and disruptive technologies; the availability of acceptable raw materials and component supply; the ability to enforce company patents; patents of third parties preventing or restricting the company's manufacture, sale or use of affected products or technology; any impact of the commercial and credit environment on Baxter and its customers; foreign currency fluctuations and other risks identified in the company's most recent filing on Form 10-K and other Securities and Exchange Commission filings, all of which are available on the company's website. The company does not undertake to update its forward-looking statements. Financial schedules are attached to this release and available on the company's website.
BAXTER INTERNATIONAL INC.
Consolidated Statements of Income
Three Months Ended September 30, 2009 and 2008
(unaudited)
(in millions, except per share and percentage data)
Three Months Ended
September 30,
2009 2008 Change
NET SALES $3,145 $3,151 0%
COST OF SALES 1,513 A 1,630 A (7%)
GROSS MARGIN 1,632 1,521 7%
% of Net Sales 51.9% 48.3% 3.6 pts
MARKETING AND ADMINISTRATIVE EXPENSES 672 681 (1%)
% of Net Sales 21.4% 21.6% (0.2 pts)
RESEARCH AND DEVELOPMENT EXPENSES 228 230 B (1%)
% of Net Sales 7.2% 7.3% (0.1 pt)
NET INTEREST EXPENSE 23 20 15%
OTHER EXPENSE, NET 51 C 28 C 82%
PRE-TAX INCOME 658 562 17%
INCOME TAX EXPENSE 126 86 D 47%
% of Pre-Tax Income 19.1% 15.3% 3.8 pts
NET INCOME 532 476 12%
LESS: NONCONTROLLING INTERESTS 2 4 (50%)
NET INCOME ATTRIBUTABLE TO BAXTER $530 $472 12%
BASIC EPS $0.88 $0.76 16%
DILUTED EPS $0.87 $0.74 18%
WEIGHTED-AVERAGE NUMBER OF COMMON SHARES OUTSTANDING
Basic 605 625
Diluted 612 638
ADJUSTED PRE-TAX INCOME (excluding specified items) $739 E $677 E 9%
ADJUSTED NET INCOME ATTRIBUTABLE TO BAXTER (excluding specified $599 E $563 E 6%
items)
ADJUSTED DILUTED EPS (excluding specified items) $0.98 E $0.88 E 11%
A Cost of sales in 2009 included a charge of $27 million ($22 million
on an after-tax basis, or $0.03 per diluted share) primarily related
to planned retirement costs associated with the SYNDEO PCA Syringe
Pump. Cost of sales in 2008 included a charge of $72 million ($65
million on an after-tax basis, or $0.10 per diluted share) related
to COLLEAGUE infusion pumps.
B Research and development (R&D) expenses in 2008 included an
in-process R&D (IPR&D) charge of $12 million ($7 million on an
after-tax basis, or $0.01 per diluted share) related to the
company's in-licensing agreement with Innocoll Pharmaceuticals Ltd.
(Innocoll).
C Other expense, net in 2009 included an impairment charge of $54
million ($47 million on an after-tax basis, or $0.08 per diluted
share) associated with the discontinuation of the company's SOLOMIX
drug delivery system in development. Other expense, net in 2008
included an impairment charge of $31 million ($19 million on an
after-tax basis, or $0.03 per diluted share) associated with the
discontinuation of the CLEARSHOT pre-filled syringe program.
D Income tax expense in 2008 included a net benefit of $15 million, or
$0.02 per diluted share, related primarily to the reversal of a
valuation allowance, partially offset by tax expense associated with
foreign earnings that the company planned to repatriate to the
United States.
E Refer to page 9 for a description of the adjustments and a
reconciliation of GAAP (generally accepted accounting principles)
measures.
Note: The consolidated statements of income reflect the January 1,
2009 adoption of a new accounting standard that requires a company
to present a consolidated net income measure that includes the
amount attributable to noncontrolling interests (historically
referred to as minority interests) for all periods presented. Prior
to January 1, 2009, the noncontrolling interests' share of net
income was included in other expense, net.
BAXTER INTERNATIONAL INC.
Notes to Consolidated Statements of Income
Three Months Ended September 30, 2009 and 2008
Description of Adjustments and Reconciliation of GAAP to Non-GAAP
Measures
(unaudited)
(in millions, except per share and percentage data)
2009 description of adjustments
and reconciliation of GAAP to Non-GAAP
The company's GAAP results for the three months ended September 30,
2009 included an impairment charge associated with the
discontinuation of the company's SOLOMIX drug delivery system in
development and a charge primarily related to planned retirement
costs associated with the SYNDEO PCA Syringe Pump, which impacted
the GAAP results as follows:
Income Net Income
Pre-tax Tax Attributable Diluted
Income Expense to Baxter EPS
GAAP $658 $126 $530 $0.87
Impairment charge 54 7 47 0.08
Infusion pump charge (1) 27 5 22 0.03
Excluding specified items $739 $138 $599 $0.98
Effective tax rate 18.7%
(1) Included in the cost of sales line within the accompanying
consolidated statements of income. Excluding this item, adjusted
gross margin was $1.66 billion and the adjusted gross margin
percentage was 52.8%.
2008 description of adjustments
and reconciliation of GAAP to Non-GAAP
The company's GAAP results for the three months ended September 30,
2008 included a charge related to COLLEAGUE infusion pumps, an
impairment charge associated with the discontinuation of the
CLEARSHOT pre-filled syringe program, and an IPR&D charge related to
the company's in-licensing agreement with Innocoll, which impacted
the GAAP results as follows:
Income Net Income
Pre-tax Tax Attributable Diluted
Income Expense to Baxter EPS
GAAP $562 $86 $472 $0.74
Infusion pump charge (1) 72 7 65 0.10
Impairment charge 31 12 19 0.03
IPR&D charge (2) 12 5 7 0.01
Excluding specified items $677 $110 $563 $0.88
Effective tax rate 16.2%
(1) Included in the cost of sales line within the accompanying
consolidated statements of income. Excluding this item, adjusted
gross margin was $1.59 billion and the adjusted gross margin
percentage was 50.6%.
(2) Included in the R&D expenses line within the accompanying
consolidated statements of income. Excluding this item, adjusted R&D
expenses were $218 million, or 6.9% of net sales.
For more information on the company's use of non-GAAP financial
measures in this press release, please see the company's Current
Report on Form 8-K filed with the Securities and Exchange Commission
on the date of this press release.
BAXTER INTERNATIONAL INC.
Consolidated Statements of Income
Nine Months Ended September 30, 2009 and 2008
(unaudited)
(in millions, except per share and percentage data)
Nine Months Ended
September 30,
2009 2008 Change
NET SALES $9,092 $9,217 (1%)
COST OF SALES 4,334 A 4,689 A (8%)
GROSS MARGIN 4,758 4,528 5%
% of Net Sales 52.3% 49.1% 3.2 pts
MARKETING AND ADMINISTRATIVE EXPENSES 1,943 2,024 (4%)
% of Net Sales 21.4% 22.0% (0.6 pts)
RESEARCH AND DEVELOPMENT EXPENSES 671 642 B 5%
% of Net Sales 7.4% 7.0% 0.4 pts
NET INTEREST EXPENSE 73 62 18%
OTHER EXPENSE, NET 52 C 25 C 108%
PRE-TAX INCOME 2,019 1,775 14%
INCOME TAX EXPENSE 380 319 D 19%
% of Pre-Tax Income 18.8% 18.0% 0.8 pts
NET INCOME 1,639 1,456 13%
LESS: NONCONTROLLING INTERESTS 6 11 (45%)
NET INCOME ATTRIBUTABLE TO BAXTER $1,633 $1,445 13%
BASIC EPS $2.68 $2.30 17%
DILUTED EPS $2.66 $2.26 18%
WEIGHTED-AVERAGE NUMBER OF COMMON SHARES OUTSTANDING
Basic 608 628
Diluted 615 640
ADJUSTED PRE-TAX INCOME (excluding specified items) $2,100 E $1,943 E 8%
ADJUSTED NET INCOME ATTRIBUTABLE TO BAXTER (excluding specified $1,702 E $1,581 E 8%
items)
ADJUSTED DILUTED EPS (excluding specified items) $2.77 E $2.47 E 12%
A Cost of sales in 2009 included a charge of $27 million ($22 million
on an after-tax basis, or $0.03 per diluted share) primarily related
to planned retirement costs associated with the SYNDEO PCA Syringe
Pump. Cost of sales in 2008 included charges totaling $125 million
($110 million on an after-tax basis, or $0.17 per diluted share)
related to COLLEAGUE infusion pumps.
B R&D expenses in 2008 included an IPR&D charge of $12 million ($7
million on an after-tax basis, or $0.01 per diluted share) related
to the company's in-licensing agreement with Innocoll.
C Other expense, net in 2009 included an impairment charge of $54
million ($47 million on an after-tax basis, or $0.08 per diluted
share) associated with the discontinuation of the company's SOLOMIX
drug delivery system in development. Other expense, net in 2008
included an impairment charge of $31 million ($19 million on an
after-tax basis, or $0.03 per diluted share) associated with the
discontinuation of the CLEARSHOT pre-filled syringe program.
D Income tax expense in 2008 included a net benefit of $15 million, or
$0.02 per diluted share, related primarily to the reversal of a
valuation allowance, partially offset by tax expense associated with
foreign earnings that the company planned to repatriate to the
United States.
E Refer to page 11 for a description of the adjustments and a
reconciliation of GAAP measures.
Note: The consolidated statements of income reflect the January 1,
2009 adoption of a new accounting standard that requires a company
to present a consolidated net income measure that includes the
amount attributable to noncontrolling interests (historically
referred to as minority interests) for all periods presented. Prior
to January 1, 2009, the noncontrolling interests' share of net
income was included in other expense, net.
BAXTER INTERNATIONAL INC.
Notes to Consolidated Statements of Income
Nine Months Ended September 30, 2009 and 2008
Description of Adjustments and Reconciliation of GAAP to Non-GAAP
Measures
(unaudited)
(in millions, except per share and percentage data)
2009 description of adjustments
and reconciliation of GAAP to Non-GAAP
The company's GAAP results for the nine months ended September 30,
2009 included an impairment charge associated with the
discontinuation of the company's SOLOMIX drug delivery system in
development and a charge primarily related to planned retirement
costs associated with the SYNDEO PCA Syringe Pump, which impacted
the GAAP results as follows:
Income Net Income
Pre-tax Tax Attributable Diluted
Income Expense to Baxter EPS
GAAP $2,019 $380 $1,633 $2.66
Impairment charge 54 7 47 0.08
Infusion pump charge (1) 27 5 22 0.03
Excluding specified items $2,100 $392 $1,702 $2.77
Effective tax rate 18.7%
(1) Included in the cost of sales line within the accompanying
consolidated statements of income. Excluding this item, adjusted
gross margin was $4.79 billion and the adjusted gross margin
percentage was 52.6%.
2008 description of adjustments
and reconciliation of GAAP to Non-GAAP
The company's GAAP results for the nine months ended September 30,
2008 included charges related to COLLEAGUE infusion pumps, an
impairment charge associated with the discontinuation of the
CLEARSHOT pre-filled syringe program, and an IPR&D charge related to
the company's in-licensing agreement with Innocoll, which impacted
the GAAP results as follows:
Income Net Income
Pre-tax Tax Attributable Diluted
Income Expense to Baxter EPS
GAAP $1,775 $319 $1,445 $2.26
Infusion pump charges (1) 125 15 110 0.17
Impairment charge 31 12 19 0.03
IPR&D charge (2) 12 5 7 0.01
Excluding specified items $1,943 $351 $1,581 $2.47
Effective tax rate 18.1%
(1) Included in the cost of sales line within the accompanying
consolidated statements of income. Excluding this item, adjusted
gross margin was $4.65 billion and the adjusted gross margin
percentage was 50.5%.
(2) Included in the R&D expenses line within the accompanying
consolidated statements of income. Excluding this item, adjusted R&D
expenses were $630 million, or 6.8% of net sales.
For more information on the company's use of non-GAAP financial
measures in this press release, please see the company's Current
Report on Form 8-K filed with the Securities and Exchange Commission
on the date of this press release.
BAXTER INTERNATIONAL INC.
Cash Flows from Operations and Changes in Net Debt
(unaudited)
($ in millions)
Cash Flows from Operations
(Brackets denote cash outflows) Three Months Ended Nine Months Ended
September 30, September 30,
2009 2008 2009 2008
Net income $532 $476 $1,639 $1,456
Adjustments
Depreciation and amortization 164 165 466 481
Deferred income taxes 53 54 188 164
Stock compensation 32 38 106 111
Realized excess tax benefits from stock issued under employee (7 ) (28 ) (88 ) (28 )
benefit plans (1)
Infusion pump charges 27 72 27 125
Impairment charges 54 31 54 31
IPR&D charge - 12 - 12
Other 21 - 35 16
Changes in balance sheet items
Accounts and other current receivables (50 ) 7 (108 ) (86 )
Inventories (31 ) (52 ) (116 ) (207 )
Accounts payable and accrued liabilities 101 18 (163 ) (236 )
Restructuring payments (7 ) (9 ) (35 ) (35 )
Other( 2) (14 ) 29 (82 ) 91
Cash flows from operations $875 $813 $1,923 $1,895
Changes in Net Debt
Increase (decrease) Three Months Ended Nine Months Ended
September 30, September 30,
2009 2008 2009 2008
Net debt, beginning of period $2,030 $1,087 $1,625 $550
Cash flows from operations (875 ) (813 ) (1,923 ) (1,895 )
Capital expenditures 247 251 634 615
Dividends 157 136 475 411
Proceeds and realized excess tax benefits from stock issued under (85 ) (302 ) (289 ) (547 )
employee benefit plans
Purchases of treasury stock 100 589 966 1,522
Acquisitions of and investments in businesses and technologies 54 12 156 73
Payments related to settlements of cross-currency swaps - 241 - 542
Other, including the effect of exchange rate changes (30 ) 28 (46 ) (42 )
(Decrease) increase in net debt (432 ) 142 (27 ) 679
Net debt, September 30 $1,598 $1,229 $1,598 $1,229
Key statistics, September 30:
Days sales outstanding 58.4 55.6 58.4 55.6
Inventory turns 2.2 2.4 2.2 2.4
Selected balance sheet information: September 30, 2009 December 31, 2008
Cash and equivalents $2,571 $2,131
Accounts and other current receivables $2,229 $1,980
Inventories $2,628 $2,361
Accounts payable and accrued liabilities $3,435 $3,241
(1)In accordance with GAAP, realized excess tax benefits from stock
issued under employee benefit plans are presented in the statement
of cash flows as an outflow within the operating section and an
inflow within the financing section.
(2)Other cash flows from operations in the first quarter of 2009
included a planned contribution of $100 million to the company's
pension plan in the United States.
BAXTER INTERNATIONAL INC.
Net Sales
Periods Ending September 30, 2009 and 2008
(unaudited)
($ in millions)
Q3 Q3 % Growth @ % Growth @ YTD YTD % Growth @ % Growth @
2009 2008 Actual Rates Constant Rates 2009 2008 Actual Rates Constant Rates
BioScience
United States $675 $617 9 % 9 % $1,968 $1,754 12 % 12 %
International 710 737 (4 %) 7 % 2,087 2,195 (5 %) 9 %
Total $1,385 $1,354 2 % 8 % $4,055 $3,949 3 % 11 %
Medication Delivery
United States $550 $527 4 % 4 % $1,610 $1,555 4 % 4 %
International 618 630 (2 %) 9 % 1,727 1,831 (6 %) 10 %
Total $1,168 $1,157 1 % 7 % $3,337 $3,386 (1 %) 7 %
Renal
United States $97 $95 2 % 2 % $285 $290 (2 %) (2 %)
International 479 498 (4 %) 4 % 1,356 1,459 (7 %) 4 %
Total $576 $593 (3 %) 4 % $1,641 $1,749 (6 %) 3 %
Baxter excluding Transfusion Therapies
United States $1,322 $1,239 7 % 7 % $3,863 $3,599 7 % 7 %
International 1,807 1,865 (3 %) 7 % 5,170 5,485 (6 %) 8 %
Total $3,129 $3,104 1 % 7 % $9,033 $9,084 (1 %) 8 %
Transfusion Therapies( 1)
United States $10 $33 (70 %) (70 %) $35 $93 (62 %) (62 %)
International 6 14 (57 %) (50 %) 24 40 (40 %) (28 %)
Total $16 $47 (66 %) (64 %) $59 $133 (56 %) (52 %)
Baxter International Inc.
United States $1,332 $1,272 5 % 5 % $3,898 $3,692 6 % 6 %
International 1,813 1,879 (4 %) 7 % 5,194 5,525 (6 %) 8 %
Total $3,145 $3,151 0 % 6 % $9,092 $9,217 (1 %) 7 %
(1) Represents revenues associated with manufacturing, distribution and
other services provided by the company to the buyer of the
Transfusion Therapies (TT) business after the February 2007
divestiture.
BAXTER INTERNATIONAL INC.
Key Product Line Sales
Periods Ending September 30, 2009 and 2008
(unaudited)
($ in millions)
Q3 Q3 % Growth @ % Growth @ YTD YTD % Growth @ % Growth @
2009 2008 Actual Rates Constant Rates 2009 2008 Actual Rates Constant Rates
BioScience
Recombinants $528 $516 2 % 7 % $1,494 $1,460 2 % 10 %
Plasma Proteins 331 338 (2 %) 7 % 958 889 8 % 20 %
Antibody Therapy 336 307 9 % 12 % 1,017 908 12 % 16 %
Regenerative Medicine 109 104 5 % 10 % 317 307 3 % 11 %
Other (1) 81 89 (9 %) 0 % 269 385 (30 %) (21 %)
Total BioScience $1,385 $1,354 2 % 8 % $4,055 $3,949 3 % 11 %
Medication Delivery
IV Therapies $396 $403 (2 %) 6 % $1,124 $1,182 (5 %) 6 %
Global Injectables 433 403 7 % 13 % 1,222 1,164 5 % 14 %
Infusion Systems 208 235 (11 %) (8 %) 612 684 (11 %) (5 %)
Anesthesia 123 112 10 % 14 % 352 333 6 % 12 %
Other 8 4 100 % 125 % 27 23 17 % 0 %
Total Medication Delivery $1,168 $1,157 1 % 7 % $3,337 $3,386 (1 %) 7 %
Renal
PD Therapy $473 $480 (1 %) 5 % $1,347 $1,404 (4 %) 4 %
HD Therapy 103 113 (9 %) (1 %) 294 345 (15 %) (4 %)
Total Renal $576 $593 (3 %) 4 % $1,641 $1,749 (6 %) 3 %
Baxter excluding Transfusion Therapies $3,129 $3,104 1 % 7 % $9,033 $9,084 (1 %) 8 %
Transfusion Therapies( 2) $16 $47 (66 %) (64 %) $59 $133 (56 %) (52 %)
Total Baxter $3,145 $3,151 0 % 6 % $9,092 $9,217 (1 %) 7 %
(1) Principally includes vaccines and sales of plasma to third parties.
(2) Represents revenues associated with manufacturing, distribution and
other services provided by the company to the buyer of the TT
business after the February 2007 divestiture.
BAXTER INTERNATIONAL INC.
Key Product Line Sales by US and International
Three-Month Periods Ending September 30, 2009 and 2008
(unaudited)
($ in millions)
Q3 2009 Q3 2008 % Growth
US International Total US International Total US International Total
BioScience
Recombinants $237 $291 $528 $220 $296 $516 8 % (2 %) 2 %
Plasma Proteins 126 205 331 108 230 338 17 % (11 %) (2 %)
Antibody Therapy 239 97 336 217 90 307 10 % 8 % 9 %
Regenerative Medicine 62 47 109 55 49 104 13 % (4 %) 5 %
Other( 1) 11 70 81 17 72 89 (35 %) (3 %) (9 %)
Total BioScience $675 $710 $1,385 $617 $737 $1,354 9 % (4 %) 2 %
Medication Delivery
IV Therapies $122 $274 $396 $115 $288 $403 6 % (5 %) (2 %)
Global Injectables 228 205 433 209 194 403 9 % 6 % 7 %
Infusion Systems 118 90 208 133 102 235 (11 %) (12 %) (11 %)
Anesthesia 81 42 123 70 42 112 16 % 0 % 10 %
Other 1 7 8 0 4 4 100 % 75 % 100 %
Total Medication Delivery $550 $618 $1,168 $527 $630 $1,157 4 % (2 %) 1 %
Renal
PD Therapy $76 $397 $473 $73 $407 $480 4 % (2 %) (1 %)
HD Therapy 21 82 103 22 91 113 (5 %) (10 %) (9 %)
Total Renal $97 $479 $576 $95 $498 $593 2 % (4 %) (3 %)
Baxter excluding Transfusion Therapies $1,322 $1,807 $3,129 $1,239 $1,865 $3,104 7 % (3 %) 1 %
Transfusion Therapies( 2) $10 $6 $16 $33 $14 $47 (70 %) (57 %) (66 %)
Total Baxter $1,332 $1,813 $3,145 $1,272 $1,879 $3,151 5 % (4 %) 0 %
(1) Principally includes vaccines and sales of plasma to third parties.
(2) Represents revenues associated with manufacturing, distribution and
other services provided by the company to the buyer of the TT
business after the February 2007 divestiture.
SOURCE: Baxter International Inc.
Baxter International Inc. Media Contact: Deborah Spak, (847) 948-2349 or Investor Contacts: Mary Kay Ladone, (847) 948-3371 Clare Trachtman, (847) 948-3085
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302
© Copyright 2009 The Connors Group, Inc.